Last reviewed · How we verify
F. Johannes Plate — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Methylprednisolone 4 milligram Tab | Methylprednisolone 4 milligram Tab | marketed | Glucocorticoid | Glucocorticoid receptor (GR) | Immunology, Rheumatology, Endocrinology |
Therapeutic area mix
- Immunology, Rheumatology, Endocrinology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Bristol-Myers Squibb · 1 shared drug class
- ClinAmygate · 1 shared drug class
- First Affiliated Hospital of Wenzhou Medical University · 1 shared drug class
- First Affiliated Hospital of Zhejiang University · 1 shared drug class
- GlaxoSmithKline · 1 shared drug class
- Guangdong Hengrui Pharmaceutical Co., Ltd · 1 shared drug class
- Guangzhou JOYO Pharma Co., Ltd · 1 shared drug class
- Ain Shams University · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for F. Johannes Plate:
- F. Johannes Plate pipeline updates — RSS
- F. Johannes Plate pipeline updates — Atom
- F. Johannes Plate pipeline updates — JSON
Cite this brief
Drug Landscape (2026). F. Johannes Plate — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/f-johannes-plate. Accessed 2026-05-16.